Company intelligence / Profile preview
Xenon Pharmaceuticals
Burnaby, British Columbia, Canadaxenon-pharma.com ↗
- Ownership
- Public · XENE
- Employees
- ~251
- Development stage
- Other
01
Overview
Xenon's lead asset, azetukalner (formerly XEN1101), a Kv7 potassium channel opener, is in multiple Phase 3 trials for focal onset seizures and primary generalized tonic-clonic seizures. The company also plans to initiate a Phase 3 program in major depressive disorder. Previous studies have shown promising efficacy and safety data in epilepsy patients; long-term open-label extension studies are ongoing to further assess durability of effect and safety profile.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Collaborations with pharmaceutical partners for development/commercialization; specific partners not named in public sources but historical investors include Roche Venture Fund and Takeda Ventures
04
Financials
- Market cap
- $3.6B
- Total revenue
- $7.5M
- Enterprise value
- $2.7B
Beyond the preview
Go deeper on Xenon Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xenon Pharmaceuticals.